CD19 and acute lymphoblastic leukemia: According to the results of reported clinical trials, over 80% complete remission was acquired in refractory or relapsed B-cell acute lymphoblastic leukemia (r/r B-ALL) patients after CD19-CART cell treatment [2], and 85% complete remission was reached in acute lymphoblastic leukemia (ALL) patients [3].